Theranostics 2020; 10(2):925-937. doi:10.7150/thno.35989
Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET
1. Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University, 72076 Tübingen, Germany
2. Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, 72076 Tübingen, Germany
3. Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", Eberhard Karls University, 72076 Tübingen, Germany
4. Department of Internal Medicine, University of Genoa, Italy
5. Department of Internal Medicine II, Eberhard Karls University, 72076 Tübingen, Germany
6. Department of Dermatology, Eberhard Karls University, 72076 Tübingen, Germany
7. Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, Eberhard Karls University, 72076 Tübingen, Germany
8. Department of Mathematics "Tullio Levi-Civita", University of Padua, Italy
9. Nuclear Medicine Unit, Department of Health Sciences, University of Genoa, Italy
10. Department of Diagnostic and Interventional Radiology, Eberhard Karls University, 72076 Tübingen, Germany
11. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tübingen, 72076 Tübingen, Germany
* Contributed equally
Schwenck J, Schörg B, Fiz F, Sonanini D, Forschner A, Eigentler T, Weide B, Martella M, Gonzalez-Menendez I, Campi C, Sambuceti G, Seith F, Quintanilla-Martinez L, Garbe C, Pfannenberg C, Röcken M, Fougere Cl, Pichler BJ, Kneilling M. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo 18F-FDG-PET. Theranostics 2020; 10(2):925-937. doi:10.7150/thno.35989. Available from http://www.thno.org/v10p0925.htm
Purpose: Cancer immunotherapy depends on a systemic immune response, but the basic underlying mechanisms are still largely unknown. Despite the very successful and widespread use of checkpoint inhibitors in the clinic, the majority of cancer patients do not benefit from this type of treatment. In this translational study, we investigated whether noninvasive in vivo positron emission tomography (PET) imaging using 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) is capable of detecting immunotherapy-associated metabolic changes in the primary and secondary lymphoid organs and whether this detection enables the prediction of a successful anti-cancer immune response.
Methods: RIP1-Tag2 mice with progressed endogenous insular cell carcinomas underwent a combined cancer immunotherapy consisting of CD4+ T cells plus monoclonal antibodies (mAbs) against programmed death ligand-1 (PD-L1) and lymphocyte activation gene-3 (LAG-3) or a sham treatment after radiation-mediated immune cell depletion. A second cohort of RIP1-Tag2 mice underwent exclusive checkpoint inhibitor therapy (CIT) using anti-PD-L1/LAG-3 mAbs or sham treatment without initial immune cell depletion to mimic the clinical situation.
All mice were monitored by 18F-FDG-PET combined with anatomical magnetic resonance imaging (MRI). In addition, we retrospectively analyzed PET / computed tomography (CT) scans (PET/CT) regarding 18F-FDG uptake of CIT-treated metastatic melanoma patients in the spleen (n=23) and bone marrow (BM; n=20) as well as blood parameters (n=17-21).
Results: RIP1-Tag2 mice with advanced insular cell carcinomas treated with combination immunotherapy exhibited significantly increased 18F-FDG uptake in the spleen compared to sham-treated mice. Histopathology of the spleens from treated mice revealed atrophy of the white pulp with fewer germinal centers and an expanded red pulp with hyperplasia of neutrophils than those of sham-treated mice. Immunohistochemistry and flow cytometry analyses of the spleens revealed a lower number of T cells and a higher number of neutrophils compared to those in the spleens of sham-treated mice. Flow cytometry of the BM showed enhanced activation of T cells following the treatment schemes that included checkpoint inhibitors. The ratio of 18F-FDG uptake at baseline to the uptake at follow-up in the spleens of exclusively CIT-treated RIP1-Tag2 mice was significantly enhanced, but the ratio was not enhanced in the spleens of the sham-treated littermates. Flow cytometry analysis confirmed a reduced number of T cells in the spleens of exclusively CIT-treated mice compared to that of sham-treated mice. A retrospective analysis of clinical 18F-FDG-PET/CT scans revealed enhanced 18F-FDG uptake in the spleens of some successfully CIT-treated patients with metastatic melanoma, but there were no significant differences between responders and non-responders. The analysis of the BM in clinical 18F-FDG-PET/CT scans with a computational segmentation tool revealed significantly higher baseline 18F-FDG uptake in patients who responded to CIT than in non-responders, and this relationship was independent of bone metastasis, even in the baseline scan.
Conclusions: Thus, we are presenting the first translational study of solid tumors focusing on the metabolic patterns of primary and secondary lymphoid organs induced by the systemic immune response after CIT. We demonstrate that the widely available 18F-FDG-PET modality is an applicable translational tool that has high potential to stratify patients at an early time point.
Keywords: Checkpoint inhibitor therapy, response assessment of immunotherapy, PET/CT, translational, imaging of primary and secondary lymphatic organs
After many years of being explored in experimental studies, immunotherapeutic approaches against cancer are now successfully applied in routine clinical practice . Currently, checkpoint inhibitor therapy (CIT) applying the immune checkpoint-specific antibodies against the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4; ipilimumab) and programmed cell death protein-1 (PD-1; nivolumab and pembrolizumab) are approved as first-line treatments for patients with metastatic melanoma . Nevertheless, only a portion of these patients benefit from CIT, and many patients suffer from severe side effects independent of treatment success or failure . CIT with CTLA-4-blocking mAbs is efficient in approximately 20 % of patients with metastatic melanoma, and with PD-1 mAbs in approximately 40 % of patients. Combining CTLA-4 mAbs with PD-1 mAbs significantly increases the treatment response rate to 60 %, but the combination leads to more severe side effects. Nevertheless, 40-80 % of metastatic melanoma patients do not respond to CIT, and half of the non-responders progress rapidly [4, 5]. Consequently, as the window of opportunity to change a treatment protocol for patients with rapidly progressing metastatic melanoma is very narrow, the early identification of CIT responders is essential. Additionally, early identification of non-responders would help to limit the tremendous costs of CIT treatment that threatens the health care systems [6, 7].
There is growing evidence that successful cancer immunotherapy requires a systemic anti-tumor response involving primary (e.g. the bone marrow) and secondary lymphoid organs (e.g. the spleen) as well as a complex interplay between different immune cell populations . Unfortunately, the exact mechanisms and dynamics are still unclear. To date, there is no reliable method available for the in vivo assessment of successful anticancer immune responses, which could provide treatment stratification of patients which are responding to checkpoint inhibitor treatment . Different molecular analysis methods, such as mutational load and PD-L1 expression, have been proven as valuable predictive biomarkers but apply only to a minority of patients . However, these methods require usable tissue material, derived from invasive biopsies or resection of primary tumors, and do not take tumor heterogeneity into account.
Molecular imaging, such as positron emission tomography (PET), enables the temporal and spatial quantification of target-specific molecular probes. PET with the glucose analog 18F-FDG is widely used in the clinical routine to detect primary tumors and metastases, e.g., melanomas .
As immune cells, such as T cells, undergo specific metabolic changes upon activation and quickly switch to extensive glycolysis , we employed 18F-FDG-PET to identify the metabolic patterns induced by a successful immune response against tumors. In RIP1-Tag2 mice, a well-established tumor model of endogenous insular cell carcinomas , in vivo 18F-FDG PET/MRI identified metabolic activation of the spleen caused by the immunotherapy using anti-PD-L1/anti-LAG-3 mAbs combined with (combo) or without (CIT) the adoptive transfer of tumor antigen-specific Th1 cells. To evaluate whether our preclinical findings could potentially be translated into the clinic, we retrospectively investigated the 18F-FDG PET/CT scans of metastatic melanoma patients before and after the onset of checkpoint inhibitor therapy.
Materials and Methods
Transgenic RIP1-Tag2 mice and transgenic Tag2-TCR mice, both on a C3H background , were bred and maintained under specific pathogen-free conditions. All animal experiments were performed according to the German Animal Protection Law with permission from the local authorities (Regierungspräsidium Tübingen, Germany). The therapeutic approaches are outlined in Figure 1A and 2A as well as described in detail in the supplementary material.
Histopathology and immunohistochemistry of the spleen
The spleens of the first cohort of combo-, CIT-, Th1- or sham-treated RIP1-Tag2 mice were isolated after four weeks of treatment and fixed in 4 % formalin. Serial sections (3-5 µm thick) of the paraffin-embedded tissue were stained with hematoxylin and eosin (H&E). Immunohistochemistry staining for CD3 (SP7, DCS, 1:200, Hamburg, Germany), B220 (BD Biosciences, 1:50, NJ, USA), and myeloperoxidase (MPO, Thermo Scientific, ready-to-use, Fremont, USA) was performed on an automated immunostainer (Discovery, Ventana Medical Systems, Roche Diagnostics, Germany) according to the company's protocols for open procedures with slight modifications. For quantification, CD3- and MPO-positive cells were manually counted in three different fields with a 20x objective (200x magnification) (combo-treated: n=5; sham-treated: n=4).
Preclinical PET and MR imaging and data analysis
The PET and MR images of the first cohort of the combo- (n=4), CIT- (n=2), Th1- (n=3) or sham-treated (n=3) RIP1-Tag2 mice were acquired four days after the final mAb administration (Figure 1A) using a dedicated small-animal PET scanner (Siemens Preclinical Solutions; Knoxville, USA) and a 7 T small-animal MRI (Bruker Biospin MRI; Germany). The second cohort of CIT- (n=8) or sham-treated (n=8) RIP1-Tag2 mice underwent a baseline PET scan one day before the onset of treatment and a second PET scan four days after the fourth mAb administration (Figure 2A).
After a fasting period, the RIP1-Tag2 mice were intravenously (i.v.) injected with 12.5 MBq 18F-FDG. Static PET scans were acquired 45 min after the tracer injection for a single time frame of 15 min. The tracer injections, tracer uptake and PET and MRI scans were carried out under 1.5 % isoflurane anesthesia (mixed with 100 % oxygen) using a dedicated vaporizer (Vetland, Louisville, USA) and heat lamps.
Volumes of interest (VOIs) of the spleens were created based on the MR images before they were fused to the respective PET scans using Inveon Reserch Workplace (Siemens Preclinical Solutions). The investigator who conducted the analysis was not aware of the assignment of mice to the experimental groups.
The percent injected dose (%ID) was calculated based on the 18F-FDG Uptake (Bq/mL) in the VOIs after correction for the radioactive decay. For a visual comparison between the PET images in Figure 1D and 2D, the signal intensity as well as the color scale of the images have been adjusted with respect to each other.
Flow cytometry analysis
The spleens of the first cohort of the combo- (n=5), CIT- (n=4), Th1- (n=5) or sham-treated (n=4) RIP1-Tag2 mice as well as the spleens of the second cohort of the CIT- (n=5) or sham-treated (n=4) of RIP1Tag2 mice were isolated after four weeks of treatment for flow cytometry analysis. The BM from RIP1-Tag2 mice was isolated at a similar time point deriving from another trial (combo-treated: n=5, Th1-treated: n=4, CIT-treated: n=6; sham-treated: n=4). Freshly prepared single cell suspensions from the spleens or BM were labeled ex vivo using the following fluorescent monoclonal antibodies: (V500)-CD45.2 (BD Bioscience, NJ, USA), (V450)-CD3 (spleen, BD Bioscience), (FITC)-CD3 (BM; Biolegend, CA, USA), (FITC)-CD8 (BD Bioscience), (APC-Cy7)-CD4 (Thermo Fisher, MA, USA), (PE-Cy7)-CD69 (spleen; Thermo Fisher), (BV650)-CD69 (BM; Biolegend), (FITC)-B220 (Thermo Fisher), (PE)-Ly6G (BD Biosciences) and (PE-Cy7)-CD11b (BD Biosciences); the samples were analyzed by multicolor flow cytometry (LSR Fortessa; BD Biosciences). Fluorescence data were analyzed via FlowJo (FlowJo, LLC, OR, USA).
In total, the data from 39 patients with metastatic melanoma and their 18F-FDG-PET/CT scans before and after the start of therapy with CTLA-4 or PD-1 mAbs were available from a register study at the University Hospital of Tübingen (064 / 2013 BO1). For the analysis of the spleen, patients who had a second malignant disease, surgical resections of metastasis, or splenic metastasis were excluded. Additionally, we excluded uveal melanomas due to their different biological behavior (Table S1). In total, 23 patients with 18F-FDG-PET scans within 50 days before and 125 days after the start of therapy were identified for further analysis (Table S2: 14 responder: 3x nivolumab, 6x pembrolizumab, 4x ipilimumab, 1x ipilimumab + nivolumab; 9 non-responder: 1x nivolumab, 4x pembrolizumab, 5x ipilimumab).
For the analysis of the bone marrow, we excluded patients with diffuse bone metastases, bone marrow carcinosis, and previous external beam radiation therapy on bone marrow regions (Table S3: n=3; 1x responder; 2x non-responder).
The used segmentation program is able to recognize and exclude bone metastases within the trabecular volume automatically. However, to test the possible influence of tracer spillover from tumor localizations into the trabecular bone, we conducted all computations of trabecular bone activity before and after removing patients with bone metastasis. An overview about the patient selection is displayed in Figure S1.
Analysis of the clinical splenic 18F-FDG-PET/CT data
The PET scans were acquired on a Siemens Biograph PET/CT Scanner (Siemens Healthcare, Knoxville, USA) 60 min after the i.v. application of approximately 300 MBq 18F-FDG using a clinical protocol according to the in-house standards, which included a fully diagnostic contrast-enhanced CT scan (portal venous phase; 120 mL, 2.0 mL/s; Ultravist; Bayer, Leverkusen, Germany). The examined field ranged from the orbitomeatal line to the mid-thigh. The scans were performed with elevated arms. The PET data were reconstructed using an ultra-HD reconstruction including time-of-flight and point-spread functions (2 iterations, 21 subsets, Gaussian filter 2 mm) and were corrected for attenuation as well as scatter. Experienced physicians with long-standing expertise in hybrid imaging visually segmented visually the whole spleen in the CT images and copied the VOI to the coregistered PET data for semiquantitative analysis. The SUVmean was calculated using the Hermes Hybrid Viewer software (Hermes Medical Solutions, Stockholm, Sweden).
Computational analysis of the bone marrow activity
To identify and estimate the metabolic activation of the bone marrow, we applied a computational analysis to the hybrid 18F-FDG-PET/CT images. The software application is based on a segmentation analysis method and isolates the signal of the trabecular bone from that of the surrounding tissues, in particular, from the cortical bone [14-16]. Briefly, the algorithm identifies the bone border on CT images by recognizing the sharp attenuation contrast between soft tissues and the outer cortical bone as well as the boundary between the inner cortical bone and trabecular bone. After defining the trabecular bone volume, the program generates a mask, which is then transported onto the PET dataset to extract the functional information from the voxels belonging to the trabecular bone. To minimize the possible confounding factors, the mean SUV from the trabecular bone was normalized to the blood pool activity (10-slice VOI on the inferior vena cava) to obtain the target-to-background ratio (TBR) .
Separate analyses were conducted for the whole-body skeleton (entire skeletal system in the field of view of the acquired PET scans), the axial skeleton (all vertebrae and the sternum), and the appendicular bones (humerus- and upper half of the femur shafts).
Blood parameters from patients
Patients were selected as previously described. The investigated blood parameters were obtained from the laboratory values measured in the context of the clinical routine at the University Hospital Tübingen.
Blood glucose levels (BGL) were compared within the cohorts at the time point shortly before the follow-up 18F-FDG PET scans. The preclinical in vivo and ex vivo data and the clinical data derived from patients (18F-FDG uptake, blood parameters and TBR values between responders and non-responders) were compared using unpaired, two-tailed Student's t-tests. Data are displayed as the mean ± SEM. Significance is indicated in the figures by *p<0.05, **p<0.01 and ***p<0.001. The statistical analyses were performed using GraphPad Prism (GraphPad Software, CA, USA).
Preclinical combination cancer immunotherapy in mice with advanced cancer
At the onset of treatment, all RIP1-Tag2 mice had already developed progressed insula cell carcinomas in the pancreas as indicated by low blood glucose levels (BGL; inversely correlates with tumor progression ) of approximately 80 mg/dl, whereas healthy wild-type mice usually display BGLs of approximately 120 mg/dl. Our new established, highly effective combo-treatment (Figure 1A) was able to significantly increase and stabilize the BGL after 4 weeks of treatment when compared to the sham-treatment (p<0.01; Figure 1B). The Tag2-Th1 cell treatment without CIT or CIT-treatment without Tag2-Th1 cells was less efficient than the combo-treatment but nevertheless was superior to the sham-treatment at the end of the experiment (Figure 1B).
Combination cancer immunotherapy enhances the glucose metabolism of the spleen
Next, we focused on the impact of our different treatments on the glucose metabolism in the primary and secondary lymphoid organs of RIP1-Tag2 mice, as measured by 18F-FDG PET. After 4 weeks, we observed significantly higher 18F-FDG uptake in the spleens of combo-treated RIP1-Tag2 mice than in the spleens of sham-treated mice (p<0.01) (Figure 1C/D). However, as a consequence of the limited spatial resolution, we were unable to analyze the 18F-FDG uptake in the lymph nodes or bone marrow of the experimental mice.
Furthermore, we aimed to identify the cellular origin of the enhanced glucose metabolism in the spleens of RIP1-Tag2 mice. We expected that the enhanced PET signal was the consequence of an enlarged, highly activated and proliferating T cells population in the spleen. Interestingly, flow cytometry analysis revealed a significantly decreased population of CD3+ T cells in the spleens of combo-treated mice compared to the population in the spleens of sham-treated RIP1-Tag2 mice (p<0.05; Figure 1E).
When focusing on activated CD3+ T cells, flow cytometry analysis revealed a slightly enhanced CD69 expression in the exclusively Th1-treated mice but not in the combo-, CIT- or sham-treated mice (Figure 1E). Furthermore, we determined a trend towards a higher number of neutrophils and a significantly lower number of B cells in the spleens of combo-treated mice than in the spleens of sham-treated mice (p<0.05; Figure 1F).
To gain deeper insights into the combo-treatment-induced changes in spleen morphology and the distribution of T cells, B cells and neutrophils, we conducted H&E and immunohistochemical staining (for CD3, B220, MPO). We observed atrophy of the white pulp with fewer germinal centers in the spleens of combo-treated mice than in the spleens of sham-treated mice (CD3 and B220-stained sections, Figure 1G). Additionally, we determined a clear expansion of the red pulp with a strongly enhanced accumulation of neutrophils mainly surrounding the sinusoids of the red pulp (Figure 1G). In agreement with the data obtained from flow cytometry, the CD3 immunohistochemistry revealed an unexpected reduction in the number of CD3+ T cells within the spleens of combo-treated RIP1-Tag2 mice than in the spleens of sham-treated mice. MPO immunohistochemistry highlighted a strong increase in the number of MPO-expressing immune cells in the spleens of combo-treated mice compared to that in the spleens of sham-treated mice, indicating that the combo- treatment might induce an intense systemic humoral immune response associated with a change in the splenic morphology. The quantification of CD3+ T cells and MPO+ neutrophils revealed a tendency towards the sham-treated mice having half the number of CD3+ T cells as the combo-treated (Figure 1G, lower graph); additionally, there was a statistically significant 4-fold increase in the number of MPO+ neutrophils in the spleens of the combo-treated littermates when compared to sham-treated mice (p<0.01; Figure 1G, lower graph).
Combination immunotherapy causes bone marrow activation
To uncover whether combo-, single Th1- or single CIT-treatment affects the primary lymphatic organs, we conducted flow cytometry analysis of the BM of all experimental groups and determined a slightly enhanced number of CD69-expressing T cells following CIT treatment with or without Tag2-Th1 cells (CIT) when compared to sham treatment (Figure 1H, left graph). When focusing exclusively on CD3-negative cells, we determined a slightly enhanced expression of CD69 exclusively in the mice treated with Tag2-Th1 cells in combination with or without immune checkpoint blockade (Th1) compared to sham-treated mice, indicating that CIT might predominantly induce the activation of T cells and that the Tag2-Th1 cells might predominantly induce the activation of B cells (Figure 1H, right graph).
Preclinical CIT-treatment in mice with advanced cancer similar to the setting in the clinic
We aimed to mimic the clinical conditions without initial radiation and adoptive transfer of tumor antigen-specific T cells. Thus, in the second experimental setup, RIP1-Tag2 mice exclusively underwent CIT treatment without an initial immune cell depletion or Tag2-Th1 cell transfer (Figure 2A). In addition, we conducted 18F-FDG-PET/MRI investigations one day before the onset of treatment (baseline) and four days after the 4th administration of the mAbs (follow-up; Figure 2A). CIT treatment was able to induce a moderate but significant therapeutic effect on the BGLs of RIP1-Tag2 mice when compared to sham-treated mice during the course of treatment until the second 18F-FDG examination (p<0.01; Figure 2B).
Investigation of the splenic 18F-FDG uptake and splenic immune cell Infiltrate in RIP1-Tag2 mice 4 weeks after the onset of combination immunotherapy. (A) Combination immunotherapy (combo) treatment scheme for RIP1-Tag2 mice with advanced endogenous insular cell carcinomas. (B) Tumor progression was monitored via BGL in RIP1-Tag2 mice. (C) Splenic 18F-FDG uptake was determined by PET/MRI in combo- (n=4) and sham-treated (n=3) RIP1-Tag2 mice following 4 weeks of treatment and compared to the sham-treated mice (n=3). (D) Representative PET/MRI images of 18F-FDG uptake in the spleens of mice after 4 weeks of treatment. PET images were fused to MR images for anatomical coregistration. S = spleen, K = kidney, Bl = Bladder. (E, F) Flow cytometry analysis of splenic T cells (CD3), B cells (B220), neutrophils and the lymphocyte activation marker CD69 four weeks after the onset of treatment. (G) H&E and immunohistochemical staining of spleen slices revealed atrophy of the white pulp with fewer germinal centers in combo-treated mice than in sham-treated mice and a clear expansion of the red pulp with a strongly enhanced accumulation of neutrophils. Quantification of CD3+ T cells and MPO+ neutrophils in the spleens of combo-treated mice (n=5) compared to those of the sham-treated littermates (n=4). (H) Flow cytometry analysis of the BM focusing on CD69-expressing lymphocytes (left) in the combo- and CIT-treated experimental groups. The expression of CD69 by CD3-negative cells exclusively in combo- or single Th1-treated RIP1-Tag2 mice (right). Data are expressed as the mean ± SEM. Each data point represents one mouse (B-H) or the sum of three fields of one tissue slice (200x magnification). (*P<0.05, **P<0.01, ns = not significant).(Click on the image to enlarge.)
Investigation of the splenic 18F-FDG uptake and splenic immune cell infiltrate of RIP1-Tag2 mice with CIT. (A) Treatment scheme including two PET investigations before and during the treatment blockade of non-irradiated RIP1-Tag2 mice bearing advanced endogenous insular cell carcinomas. (B) Treatment monitoring via the median blood glucose levels in RIP1-Tag2 mice (n=8). (C) Changes in the uptake of 18F-FDG in the spleens of mice measured by in vivo PET between the baseline and follow-up PET scans. (D) Representative PET/MRI images showing the 18F-FDG uptake in the spleens of RIP1-Tag2 mice at the baseline (upper panel) and at the follow-up (lower panel) PET scans. Dashed line = spleen, K = kidney. (E) Changes in the spleen volumes of RIP1-Tag2 mice between the baseline and follow-up scans. CIT increased the spleen volume of RIP1-Tag2 mice after 4 injections of the antibody cocktail. (F) Flow cytometry analysis of the spleens after 4 weeks of CIT revealed less splenic CD4+ and CD8+ T cells as well as less expression of the activation marker CD69 compared to those at baseline (CD4+, CIT: 12.3±0.9 % of CD45.2+ cells; sham: 17.6±1.0 % of CD45.2+ cells, p<0.01; CD8+, CIT: 2.9±0.3 % of CD45.2+ cells; sham: 7.0±0.5 % of CD45.2+ cells, p<0.001). Data are expressed as the mean ± SEM. Each data point represents one mouse (*P<0.05, **P<0.01, ***P<0.001).(Click on the image to enlarge.)
CIT enhances the glucose metabolism of the spleen
In vivo 18F-FDG-PET/MRI scans revealed a significant increase in splenic 18F-FDG uptake from baseline to follow-up in CIT-treated mice when compared to that of sham-treated mice (p<0.05; Figure 2C/D). Moreover, we determined a significant increase in spleen volume between the baseline and follow-up scans in the CIT-treated RIP1-Tag2 mice and a decrease in spleen volume in sham-treated mice (p<0.001; Figure 2E). Finally, we conducted flow cytometry analysis of the spleens of both experimental groups and determined that the results were in line with our previous results (Figure 1E). Thus, we determined a significantly reduced number of CD3+ T cells in the spleens of the CIT-treated mice when compared to the spleens of the sham-treated littermates (p<0.01; Figure 2F). Interestingly, as indicated by CD69 expression, the CD3+ T cells were less activated after CIT-treatment than after sham-treatment (p<0.01; Figure 2F). Differential analysis of CD4+ and CD8+ T cell populations revealed that both populations in the spleens of the CIT-treated group were significantly reduced, in a similar manner, compared to those in the spleens of the sham-treated group (Figure 2F).
Retrospective analysis of clinical 18F-FDG-PET/CT scans with a focus on the spleen
To test whether our preclinical results are also valid in CIT-treated patients, we retrospectively analyzed the 18F-FDG-PET/CT data from patients with metastatic melanoma. We identified 23 patients who underwent 18F-FDG-PET/CT imaging within 50 days before and 125 days after the onset of CTLA-4 or PD-1 mAb treatment. The patients were divided into treatment responders or non-responders according to the clinical decisions made by the treating physicians, which led to the continuation or discontinuation of the CIT-treatment. No significant differences in age were identified between the two groups. One of the non-responders underwent cytotoxic chemotherapy 11 months before the onset of CIT because of an ovarian carcinoma; none of the other patients underwent chemotherapy regimens due to metastatic melanoma. Four of the non-responders (44 %) and 2 of the responders (14 %) previously received external beam irradiation of the non-bone marrow areas. Two of the responders (14 %) and 4 of the non-responders (44%) underwent interferon-alpha therapy; one of the responders and four of the non-responders were treated with a kinase inhibitor before CIT. The baseline 18F-FDG-PET/CT scans before CIT revealed no differences in the splenic 18F-FDG uptake between responders and non-responders (Figure 3A; Table S2). In line with our preclinical studies, the follow-up 18F-FDG-PET/CT scans revealed a tendency towards some patients having high 18F-FDG uptake in the spleen, but no significant differences were found between responders and non-responders when comparing the baseline 18F-FDG-PET/CT scans to the follow-up scans (Figure 3B).
Retrospective analysis of 18F-FDG uptake in the spleen of patients with metastasized melanoma during checkpoint inhibitor treatment. (A) 18F-FDG uptake between responders and non-responders at baseline before the start of treatment. A representative sample image from a patient who responded to treatment displays the physiological 18F-FDG uptake in the spleen. (B) 18F-FDG uptake at the follow-up PET scan. The sample image represents a patient who responded to checkpoint inhibitor therapy and had a slight increase in 18F-FDG uptake and an increase in spleen volume after therapy compared to before therapy (compared to 3A; identical patient). Data are expressed as the mean ± SEM (responder n=14; non-responder n=9). Each data point represents one patient (ns = not significant).(Click on the image to enlarge.)
Retrospective computational analysis of the 18F-FDG uptake in the BM
To assess the impact of CIT on BM, we used an established tool to segment the trabecular bone from the cortical bone for analysis on 18F-FDG-PET/CT-scans . From the same group of patients, we excluded three patients with diffuse bone metastases and those who previously received external beam radiation therapy on the bone marrow regions. Thus, a total of 20 patients fulfilled the inclusion criteria for this analysis (Table S3). Figure 4A (upper) represents the baseline 18F-FDG-PET scan (left) and the follow-up 18F-FDG-PET scan (right) after the initiation of CIT, and the clearly enhanced 18F-FDG uptake within the bone was a consequence of successful treatment. Figure 4A (lower) represents the baseline 18F-FDG-PET scan (left) and the follow-up 18F-FDG-PET scan (right) after the initiation of CIT, indicating rather reduced 18F-FDG uptake within the bone is a consequence of CIT failure. Patients within the responding group revealed significantly higher baseline whole-body TBR values than the non-responding group (p<0.05; Figure 4B). Importantly, this difference was present in the axial bones (p<0.01) but not in the appendicular bones (Figure 4C). After CIT, the whole-body TBR values increased by 19.0±6.8 % in responders (p<0.01) but slightly decreased in non-responders (-5.9±4.8 %; Figure 4D). In the axial skeleton, the TBR increased by 16.7±5.0 % in the responders, whereas the uptake ratio decreased in the non-responders (-9.3±4.4%, p<0.01; Figure 4E). In the appendicular bones, we observed a trend towards CIT-treated responders having increased uptake, while the uptake of the non-responders remained relatively stable (Figure 4E).
Retrospective analysis of clinical PET/CT data from the bone marrow using an automatic segmentation tool. (A) Upper PET images: representative baseline 18F-FDG-PET scan (left) and the follow-up 18F-FDG-PET scan (right) after the initiation of CIT; the clearly enhanced 18F-FDG uptake within the bone is a consequence of successful treatment. Lower PET images: representative baseline 18F-FDG-PET scan (left) and the follow-up 18F-FDG-PET scan (right) after the initiation of CIT; the rather reduced 18F-FDG uptake within the bone is a consequence of CIT failure. (B) TBRs at baseline. (C) Separate analysis of the axial and appendicular bones. (D) Percentage change of the 18F-FDG uptake in the whole-body TBR using the 18F-FDG-PET/CT scans. (E) Percentage change of the 18F-FDG uptake after a separate analysis of the axial and appendicular bones. Data are expressed as the mean ± SEM (responder n=13; non-responder n=7). Each data point represents one patient (*P<0.05, **P<0.01, ***P<0.01, ns = not significant).(Click on the image to enlarge.)
After excluding patients with bone metastasis, we obtained comparable results for the responders (n=8) and non-responders (n=4), although the differences between responders and non-responders were not significant (Figure S2A/B). The percentage change reveals significant differences between responders and non-responders (n=12; Figure S2C/D).
Retrospective analysis of blood parameters
After the onset of CIT-treatment, the routine tumor marker S100 and LDH increased in non-responders but decreased in responders (Figure S3A). Surprisingly, we observed a trend towards an elevation of the relative eosinophil count in non-responders but a decline in responders, whereas the relative lymphocyte counts declined in either responders or non-responders (Figure S3B).
As immune therapy is becoming widely applied in the clinics, the evaluation of therapy response is becoming tremendously important. Classically, the effect of cancer therapies is quantified by categories such as lesion size or 18F-FDG uptake, which are reflected by the Response Evaluation Criteria in Solid Tumors (RECIST; ) guidelines. As immune responses can be accompanied by massive glucose consumption or an increase in the volumes of the tumors or lymphatic organs, the interpretation of clinical 18F-FDG-PET/CT data is hampered by CIT.
In contrast to conventional chemotherapy, cancer immune therapy can be correlated with survival benefits for patients even after an increase in total tumor burden or in the presence of new lesions . This led to the development of new response criteria, such as iRECIST (immune related RECIST) or PERCIMT (PET response criteria for the evaluation of immunotherapy), that consider factors like pseudo progression [20, 21]. Dercle et al. analyzed the imaging patterns after three months of PD-1 mAb treatment in patients with refractory Hodgkin lymphoma and found that five of the 16 patients (31 %) exhibited new imaging patterns related to PD-1 mAb therapy that did not fit to the RECIST or Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) criteria . Additionally, the authors observed an increase in splenic 18F-FDG uptake the in Hodgkin lymphoma patients receiving PD-1 mAb therapy . Regarding solid tumors, only reports about single cases of melanoma patients describe the 18F-FDG uptake in secondary lymphoid organs, such as the spleen or lymph nodes, after cancer immunotherapy [23, 24].
Here, our translational study of the metabolic patterns in response to CIT in solid tumors was able to identify an increase in splenic glucose metabolism in an experimental murine model of insular carcinoma, which was accompanied by decreased germinal centers of B and T cells but by increased numbers of MPO+ neutrophils, compared to those in response to the sham treatment. Nevertheless, our retrospective analysis of the clinical PET/CT data could not confirm that the splenic 18F-FDG uptake of patients with metastasized melanoma was significantly enhanced (See Supplementary Discussion 1).
In the RIP1-Tag2 mouse model the blood glucose level (BGL) declines with progressing insulinomas due to its insulin production. Nevertheless, the changes in insulin secretion are not explaining our results regarding the 18F-FDG uptake of the spleen, as we would expect a higher glucose uptake in the spleen of mice with larger tumors (sham treatment) if the spleen uptake would be insulin dependent.
As the spleen volume is reduced dramatically in sham-treated mice while the 18F-FDG uptake is only slightly decreased, the measured differences in the splenic 18F-FDG uptake between sham- and CIT-treated mice are not simply an effect of the changes in the spleen volumes.
In our experiments, flow cytometry revealed reduced populations of splenic CD3+ T cells as a consequence of combo- or CIT-treatment (Figure 1E, 2F) and a trend towards some mice having an increased presence of splenic neutrophils (Figure 1F). Immunohistochemistry depicted the expansion of the red pulp with a larger number of neutrophils as well as atrophy of the white pulp with fewer germinal centers after combo-treatment than after sham treatment (Figure 1G), which is in line with the flow cytometry data. Consequently, additional studies are needed to investigate the correlation of these findings to the effect of immunotherapy. Thus, an elevated infiltration of splenic neutrophils, which are highly active metabolically, could potentially explain the high splenic glucose metabolism observed by 18F-FDG-PET in our preclinical experiments. Both, activated neutrophils and T cells exhibit a strongly elevated glucose metabolism, but the neutrophils possess less mitochondria than other immune cells and are therefore highly dependent on anaerobic glycolysis [25, 26]. Thus, the elevated 18F-FDG-uptake in the spleens of experimental mice with immunotherapy might be the consequence of the strongly elevated number of neutrophils and not T cells, which were decreasing in the spleen tissue of combo treated mice (Figure 1G). This opens new insights into the effects of an immunotherapeutic approach on the systemic immune response in a secondary lymphatic (the spleen) which was to date not reported elsewhere.
In our retrospective analysis of the clinical data, 18F-FDG-PET scans revealed only a slight increase in the glucose metabolism of the spleen in some patients, but there were no differences between responders and non-responders. Notably, patients in clinical practice are exposed to many different environmental stimuli that could potentially interact with the systemic immune response to CIT. Additionally, the unknown temporal dynamics of the immune response under CIT and the different time points of the 18F-FDG-PET scans in our retrospective study may have influenced the results.
Schwarzenberger et al. observed extramedullary splenic granulopoiesis and erythropoiesis after stimulation with IL-17 in mice . In contrast, granulopoiesis in humans switches from the liver, thymus, and spleen to the BM in the early stages of embryogenesis . This change may explain the different results we obtained from our preclinical experiments on mice and our retrospective analysis of clinical PET/CT data.
Thus, we focused on the BM as a primary lymphoid organ, especially since numerous studies have indicated that sufficient hematopoiesis is a prerequisite for successful cancer immunotherapy . The BM is the most important hematopoietic organ in adults for innate and adaptive immune cells and an important survival niche for naive and memory T cells, plasma cells, regulatory T cells and myeloid cells such as MDSCs . Increased hematopoiesis requires an enhanced metabolic rate in the BM, which leads to a high glucose uptake on the 18F-FDG PET scan [29-32]. Furthermore, increased hematopoiesis induces an expansion of the active BM to the appendicular bones [21, 24]. Unfortunately, the skeletons of mice were not able to be examined by 18F-FDG-PET in the same manner as the patient skeletons due to the limited spatial resolution of PET. Nevertheless, flow cytometry analysis of the BM revealed that CIT might induce the activation of T cells (Figure 1H, left) and that Tag2-Th1 cells might induce the activation of CD3-negative cells. (Figure 1H, right).
In our retrospective analysis of the clinical 18F-FDG-PET data, the glucose metabolism in the BM was significantly increased in patients with a clinical response to CIT compared to patients without a response to CIT (Figure 4B). In the axial skeleton, this effect was observed before the onset of treatment and in the follow-up examination, while in the appendicular skeleton, only a slight trend was noticeable in the follow-up 18F-FDG-PET scan; this difference could be due to an expansion of the active BM.
In the axial skeleton of responders, the 18F-FDG uptake in the BM increased significantly in the follow-up PET scan when compared to the baseline PET scan prior to onset of CIT. In sharp contrast, we observed a decreased 18F-FDG uptake in the BM of non-responders on the follow-up scan compared to the baseline scan (Figure 4E). A systematic review that included 12 studies with over 2,500 cancer patients who underwent 18F-FDG-PET examinations revealed a correlation between 18F-FDG uptake in the tumor and in the BM as well as the blood leukocyte count, which suggests a close relationship between the systemic inflammatory response involving BM activation and the tumor microenvironment . In our melanoma patient cohort, we observed a trend towards a high blood eosinophil count in non-responders as a consequence of CIT, but there were no significant differences in the relative neutrophil and lymphocyte counts between responders and non-responders (Figure S2). Whether our results of enhanced 18F-FDG uptake in the BM correlate with prognostic factors such as eosinophil count is unclear as the predictive power of our clinical study was limited due to the retrospective nature of the analysis and the relatively small number of patients. Weide et al. reported that elevated blood eosinophil counts prior to CIT might represent a positive prognostic factor in melanoma patients .
Novel and more sophisticated noninvasive in vivo molecular imaging methods using radiolabeled antibodies or immune cells are in preclinical development, and these methods inherently have a higher specificity than 18F-FDG-PET for the characterization of immune responses [34-37]. Nevertheless, these approaches lack the possibility of immediate clinical translation due to regulatory, organizational, or economic issues, unlike 18F-FDG-PET, which is already part of the staging routine in many cancer types.
Here, we present the first translational 18F-FDG-PET study on the impact of CIT in solid tumors on metabolic patterns in the BM and spleen. Thus, non-invasive in vivo 18F-FDG-PET/CT imaging of the glucose metabolism in the lymphatic organs might represent a powerful preclinical and clinical tool to discriminate responders from non-responders.
18F-FDG: 2-[18F]fluoro-2-deoxy-D-glucose; BGL: blood glucose level; BM: bone marrow; C3H: C3H mouse strain; CBC: complete blood count; CIT: checkpoint inhibitor therapy; CT: x-ray computed tomography; CTLA-4: cytotoxic T-lymphocyte-associated protein-4; GLUT1: transmembrane glucose transporter type 1; IFN-γ: interferon gamma; LAG-3: lymphocyte activation gene-3; LDH: lactate dehydrogenase; MRI: magnetic resonance imaging; mAbs: monoclonal antibodies; MACS: magnetic-activated cell sorting; MDSCs: myeloid derived suppressor cells; MPO: myeloperoxidase; PBS: phosphate-buffered saline; PD-1: programmed death-1; PD-L1: programmed death ligand 1; PET: positron emission tomography; RECIST: Response Evaluation Criteria in Solid Tumors; RIP1: rat insulin promotor; RIP1-Tag2: RIP1-Tag2 mice; SUV: standardized uptake value; Tag2: large T antigen; Tag2-TCR: Tag2-TCR mice; Tag2-Th1: IFN-γ-producing large T antigen (tumor antigen) -specific Th1 cells; TCR: T cell receptor; TBR: target-to-background ratio; VOI: volume of interest.
This work was supported by the Medical Faculty of the Eberhard Karls University Tübingen (“PATE program”), Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, Germany´s Excellence Strategy - EXC 2180 - 390900677 and SFB685; project B6) and the Werner Siemens-Foundation (Zug, Switzerland). Art in the graphical abstract partially adapted from Servier Medical Art https://smart.servier.com/, under license CC-BY 3.0. The authors thank Maren Harant, Natalie Mucha and Funda Cay for excellent technical support.
Supplementary figures and tables.
The authors have declared that no competing interest exists.
1. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U, Committee EG. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v126-32
2. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T. et al. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges. 2013;11(Suppl 6):1-116 1-26
3. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol. 2016;2:1346-53
4. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331:1565-70
5. Wieder T, Eigentler T, Brenner E, Rocken M. Immune checkpoint blockade therapy. J Allergy Clin Immunol. 2018;142:1403-14
6. Meng Y, Hertel N, Ellis J, Morais E, Johnson H, Philips Z. et al. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. Eur J Health Econ. 2018;19:1163-72
7. Pike E, Hamidi V, Saeterdal I, Odgaard-Jensen J, Klemp M. Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. BMJ Open. 2017;7:e014880
8. Spitzer MH, Carmi Y, Reticker-Flynn NE, Kwek SS, Madhireddy D, Martins MM. et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017;168:487-502 e15
9. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133-50
10. Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14:655-68
11. Uren RF, Howman-Giles R, Chung D, Thompson JF. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma. J Surg Oncol. 2011;104:405-19
12. Palmer CS, Ostrowski M, Balderson B, Christian N, Crowe SM. Glucose metabolism regulates T cell activation, differentiation, and functions. Front Immunol. 2015;6:1
13. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature. 2013;494:361-5
14. Fiz F, Marini C, Campi C, Massone AM, Podesta M, Bottoni G. et al. Allogeneic cell transplant expands bone marrow distribution by colonizing previously abandoned areas: an FDG PET/CT analysis. Blood. 2015;125:4095-102
15. Fiz F, Sahbai S, Campi C, Weissinger M, Dittmann H, Marini C. et al. Tumor Burden and Intraosseous Metabolic Activity as Predictors of Bone Marrow Failure during Radioisotope Therapy in Metastasized Prostate Cancer Patients. Biomed Res Int. 2017;2017:3905216
16. Sambuceti G, Brignone M, Marini C, Massollo M, Fiz F, Morbelli S. et al. Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET/CT imaging. Eur J Nucl Med Mol Imaging. 2012;39:1326-38
17. Marini C, Podesta M, Massollo M, Capitanio S, Fiz F, Morbelli S. et al. Intrabone transplant of cord blood stem cells establishes a local engraftment store: a functional PET/FDG study. J Biomed Biotechnol. 2012;2012:767369
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47
19. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-20
20. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S. et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143-e52
21. Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46:238-50
22. Dercle L, Seban RD, Lazarovici J, Schwartz LH, Houot R, Ammari S. et al. (18)F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-Programmed Death 1 Immune Checkpoint Inhibitor. J Nucl Med. 2018;59:15-24
23. Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L. et al. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016;4:58
24. Schule SC, Eigentler T, Pfannenberg C. [Multiple enlarged metabolically active lymph nodes in 18F-FDG PET/CT after anti-CTLA-4 antibody therapy in metastatic melanoma - disease progression or immunologically induced side effect?]. Rofo. 2015;187:1036-7
25. Breda CNS, Davanzo GG, Basso PJ, Saraiva Camara NO, Moraes-Vieira PMM. Mitochondria as central hub of the immune system. Redox Biol. 2019;26:101255
26. Maianski NA, Geissler J, Srinivasula SM, Alnemri ES, Roos D, Kuijpers TW. Functional characterization of mitochondria in neutrophils: a role restricted to apoptosis. Cell Death Differ. 2004;11:143-53
27. Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A. et al. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol. 1998;161:6383-9
28. Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K. et al. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin Cancer Res. 2016;22:5487-96
29. Blodgett TM, Ames JT, Torok FS, McCook BM, Meltzer CC. Diffuse bone marrow uptake on whole-body F-18 fluorodeoxyglucose positron emission tomography in a patient taking recombinant erythropoietin. Clin Nucl Med. 2004;29:161-3
30. Dobert N, Menzel C, Diehl M, Hamscho N, Zaplatnikov K, Grunwald F. Increased FDG bone marrow uptake after intracoronary progenitor cell therapy. Nuklearmedizin. 2005;44:15-9
31. Murata Y, Kubota K, Yukihiro M, Ito K, Watanabe H, Shibuya H. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT. Nucl Med Biol. 2006;33:999-1004
32. Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol. 1998;16:173-80
33. Dolan RD, McLees NG, Irfan A, McSorley ST, Horgan PG, Colville D. et al. The Relationship Between Tumor Glucose Metabolism and Host Systemic Inflammatory Responses in Patients with Cancer: A Systematic Review. J Nucl Med. 2019;60:467-71
34. Griessinger CM, Kehlbach R, Bukala D, Wiehr S, Bantleon R, Cay F. et al. In vivo tracking of Th1 cells by PET reveals quantitative and temporal distribution and specific homing in lymphatic tissue. J Nucl Med. 2014;55:301-7
35. Griessinger CM, Maurer A, Kesenheimer C, Kehlbach R, Reischl G, Ehrlichmann W. et al. 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proc Natl Acad Sci U S A. 2015;112:1161-6
36. Thunemann M, Schorg BF, Feil S, Lin Y, Voelkl J, Golla M. et al. Cre/lox-assisted non-invasive in vivo tracking of specific cell populations by positron emission tomography. Nat Commun. 2017;8:444
37. Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L. et al. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics. 2018;8:6070-87
38. Lawrence SM, Corriden R, Nizet V. The Ontogeny of a Neutrophil: Mechanisms of Granulopoiesis and Homeostasis. Microbiol Mol Biol Rev. 2018:82
39. Mercier FE, Ragu C, Scadden DT. The bone marrow at the crossroads of blood and immunity. Nat Rev Immunol. 2011;12:49-60
Corresponding author: manfred.kneillinguni-tuebingen.de telephone: +49-7071-29-83427 fax: +49-7071-29-4451